Reviewing the Data: Post LAAO Antithrombotic Therapy- 2024 Quality Summit Presentation (Non-CE)-Reviewing the Data: Post LAAO Antithrombotic Therapy

Video Transcription

Video Summary

In this session, presented by Dr. Homsi and Julie Mobaid, discussions focused on post-procedure antithrombotic therapy for patients with left atrial appendage occlusion devices like the Watchman and Amulet. Dr. Homsi highlighted the complexities involved in selecting antithrombotic regimens, emphasizing the balance between preventing thrombus formation and minimizing bleeding risks. He reviewed historical and ongoing studies, comparing various medications including DOACs, vitamin K antagonists, and antiplatelet therapies. The discussion acknowledged varying practices between Europe and the US, with European practices generally favoring antiplatelet therapies. Emerging data suggest that DOACs, even at low doses, may provide effective thromboprophylaxis with reduced bleeding risks compared to traditional treatments. Newer device iterations, such as the Watchman FlexPro, might further reduce thrombogenicity due to enhanced healing properties. Dr. Homsi emphasized patient-specific considerations and evolving strategies in optimizing post-procedural therapies. Current trials continue to explore the safety and effectiveness of these approaches, aiming to establish clearer guidelines for practitioners.

Keywords

antithrombotic therapy

left atrial appendage occlusion

Watchman

Amulet

DOACs

antiplatelet therapies

thromboprophylaxis

Watchman FlexPro

post-procedural therapies